




02-05-03



Practitioner's Docket No. 47992/58118 (formerly NIH-05065)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Samelson et al.

Serial No.: 09/597,920

Group No.: 1642

Filed: June 19, 2000

Examiner: Helms, Larry Ronald

For: THE PROTEIN TYROSINE KINASE SUBSTRATE LAT AND ITS USE IN THE IDENTIFICATION OF (ANT)AGONISTS OF THE KINASE

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

**RESPONSE UNDER
37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP
1642**

H
W
W
3503

NOTE: To take advantage of the expedited procedure the envelope in which this paper is mailed must be addressed as shown and must also be marked "Box AF" in the lower left hand corner. Alternatively, this paper can be hand carried to the particular Examining Group or other area of the Office in which the application is pending, in which case any envelope in which this paper is placed must be marked as in the bold type box above. Notice of Sept. 20, 1985 (1059 O.G. 19-20).

AMENDMENT OR RESPONSE AFTER FINAL REJECTION—TRANSMITTAL

1. Transmitted herewith is an amendment after final rejection (37 C.F.R. 1.116) for this application.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

☐ with sufficient postage as first class mail.

37 C.F.R. 1.10*

☒ as "Express Mail Post Office to Address"
Mailing Label No. EF394616843US (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Deanna M. Rivernider
Signature

Date: 2/4/03

Deanna M. Rivernider
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition."
Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

NOTE: *Response to Final Rejection—Avoiding Extension Fees* "In patent applications wherein a three month Shortened Statutory Period (SSP) is set for response to a Final Rejection, the response would best be filed within two months of the date of the Office Action. If filed within two months, any Advisory Action mailed after the SSP expires will reset the SSP to expire on the date of the Advisory Action for extension fee purposes, but never more than six months from the date of the Final Rejection." Notice of Nov. 30, 1990 (1122 O.G. 571 to 591).

STATUS

2. Applicant is
☐ a small entity. A statement:
☐ is attached.
☐ was already filed.
☒ other than a small entity.

EXTENSION OF TERM

NOTE: *As to a Supplemental Amendment filed in response to a final office action, the Notice of December 10, 1985 (1061 O.G. 34-35) states:*

"If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run."

3. (complete (a) or (b), as applicable)

- (a) ☐ Applicant petitions for an extension of time under 37 C.F.R. 1.136
(fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity
<input checked="" type="checkbox"/>	one month	\$ 110.00	\$ 55.00
<input type="checkbox"/>	two months	\$ 390.00	\$ 195.00
<input type="checkbox"/>	three months	\$ 890.00	\$ 445.00
<input type="checkbox"/>	four months	\$1,390.00	\$ 695.00

Fee: \$ 110.00

If additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

- ☐ An extension for _____ months has already been secured and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ 110.00

OR

- (b) ☐ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

SMALL ENTITY						OTHER THAN A SMALL ENTITY		
Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Addit. Fee	OR	Rate	Addit. Fee
Total	* Minus	**	=	x \$9 =	\$		x \$18 =	\$
Indep.	* Minus	***	=	x \$40 =	\$		x \$80 =	\$
[] First Presentation of Multiple Dependent Claim				+ \$135 =	\$		+ \$270 =	\$
Total						OR	Total	
Addit. Fee					\$ _____		Addit. Fee	\$ _____

- * If the entry in Col. 1 is less than the entry in Col. 2, write "O" in Col. 3.
 ** If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20".
 *** If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".
 The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

WARNING: See 37 C.F.R. § 1.116.

(complete (c) or (d), as applicable)

- (c) ☒ No additional fee is required.

OR

- (d) ☐ Total additional fee required is \$ _____.

FEE PAYMENT

5. ☒ Attached is a check in the sum of \$ 100.00.
☐ Charge Account No. _____ the sum of \$ _____.
 A duplicate of this transmittal is attached.

FEE DEFICIENCY

NOTE: Where there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the case. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. ☒ If any additional extension and/or fee is required, charge Account No. 04-1105.

AND/OR

- ☒ If any additional fee for claims is required, charge Account No. 04-1105.



SIGNATURE OF PRACTITIONER

Reg. No. 33,860

Peter F. Corless

(type or print name of practitioner)

EDWARDS & ANGELL, LLP

Dike, Bronstein, Roberts & Cushman, IP Group

P.O. Box 9169

P.O. Address

Boston, Massachusetts 02209

Tel. No. (617) 523-6440



Attorney Docket No. 47992/58118 (formerly NIH-05865)
Express Mail Label No.: EF394616843US

RECEIVED
FEB 07 2003
TECH CENTER 1608/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS	Samelson, et al.	EXAMINER:	Helms, Larry
U.S.S.N.:	09/597,920	GROUP:	1642
FILED:	June 19, 2000	Conf. No.	4586
FOR:	THE PROTEIN TYROSINE KINASE SUBSTRATE LAT AND ITS USE IN THE IDENTIFICATION OF (ANT)AGONISTS OF THE KINASE		

21/D NE
3-8-03

**RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1642**

BOX AF

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Sir:

This paper is responsive to the Final Office Action mailed August 8, 2002 and to the Advisory Action mailed October 28, 2002.

AMENDMENT

In the Specification

At page 10, after line 13, please **insert** the following:

--FIGURE 17 is a schematic diagram illustrating the role of LAT in linking the TCR to cellular activation.

FIGURE 18 is a schematic diagram showing the structure of the plasmid pEF BOS.
The boxes indicate the SV40 origin, human EI-1 α promoter region, the stuffer sequence from

NE
encl
C